AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35452022
Drug: Generalized Vestibular
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generalized Vestibular Rehabilitation Therapy (GVRT)
Trial: 35452022
Drug: Individualized Vestibular
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized Vestibular Rehabilitation Therapy (IVRT)
Trial: 35881398
Drug: Smartphone app-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone app-based education on prescribing intravenous fluids (group 1)
Trial: 35674255
Drug: MOWHTO with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOWHTO with ADMSC-injection
Trial: 32223318
Drug: Rivaroxaban (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg daily)
Trial: 32223318
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus aspirin (100 mg daily)
Trial: 34019661
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg OPK-88004 daily for 12 weeks
Trial: 34019661
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg OPK-88004 daily for 12 weeks
Trial: 34019661
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg OPK-88004 daily for 12 weeks
Trial: 33821552
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by intensity-modulated radiotherapy (IC-RT)
Trial: 33331529
Drug: Weekly working
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly working hours of the physician
Trial: 34407339
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma with a high titer of antibodies against SARS-CoV-2
Trial: 33909728
Drug: Rough-surface implants
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rough-surface implants
Trial: 33909728
Drug: Nobel Biocare
RxNorm normalized name: Lidocare
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nobel Biocare implants
Trial: 33909728
Drug: Sweden &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweden & Martina implants
Trial: 32444296
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (75 mg intramuscular injection)
Trial: 36599365
Drug: Individual Shear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Shear Rate Therapy (ISRT)
Trial: 32503946
Drug: ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab 10 mg/kg
Trial: 36529089
Drug: Extended-release calcifediol
RxNorm normalized name: calcifediol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release calcifediol (ERC)
Trial: 32503365
Drug: Stress management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress management counseling (individual sessions, four sessions, twice a week at 35 and 36 weeks of gestation)
Trial: 36098670
Drug: Deutetrabenazine (24,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine (24, 48, and 72 mg)
Trial: 33039853
Drug: Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Therapy + Expiratory Flow Acceleration (EFA)
Trial: 37913818
Drug: Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Therapy (ST)
Trial: 34843078
Drug: Nalbuphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (0.1 mg/kg) combined with propofol
Trial: 35949399
Drug: C arm
RxNorm normalized name: Drive Cast Protec Arm 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C arm (standard 4-drug combination pending phenotypic results)
Trial: 35575454
Drug: Ultrasound-guided suprascapular
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided suprascapular nerve blocks with ropivacaine 5 mL 2 mg/mL
Trial: 35575454
Drug: Ultrasound-guided injections
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided injections of 5 mL sterile saline solution (NaCl 0.9%)
Trial: 33185374
Drug: Epidural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural saline injection while supine (A group)
Trial: 33185374
Drug: Epidural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural saline injection in sitting position (B group)
Trial: 35881420
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (fosinopril or hydrochlorothiazide alone or combined with a statin)
Trial: 33404758
Drug: Milk supplemented
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk supplemented with 107 CFU/mL of Lactobacillus rhamnosus SP1
Trial: 33342316
Drug: Ingestion-time hypertension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion-time hypertension trials following minimum guidelines for treatment timing based on internal biological time (morning vs evening) and assessed using ABPM.
Trial: 33342316
Drug: ABPM performed
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABPM performed with validated devices at least hourly throughout two or more consecutive 24 h periods.
Trial: 33059620
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of HIV positive not on antiretroviral treatment to HIV negative using def1
Trial: 32408868
Drug: Iyengar-based yoga
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iyengar-based yoga intervention (twice weekly group classes and once weekly home practice for 12 weeks)
Trial: 35509178
Drug: Gadolinium-based contrast
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium-based contrast agents
Trial: 36053298
Drug: Oral OXT
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral OXT (24 IU)
Trial: 37153702
Drug: Intranasal OXT
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal OXT
Trial: 36227461
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical treatment (OMT arm)
Trial: 33357480
Drug: Lenalidomide maintenance
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide maintenance (15 mg per day for platelets >100×10^9 cells/L or 10 mg per day for platelets 60-100×10^9 cells/L, days 1-21 every 28 days) for 24 months
Trial: 32988822
Drug: Continuous Infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Infusion (CI) of cloxacillin (two 75-mg/kg 12-h infusions per day for 3 days)
Trial: 32988822
Drug: Intermittent Infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent Infusion (ItI) of cloxacillin (four 37.5-mg/kg 1-h infusions per day for 3 days)
Trial: 35759680
Drug: 6‐days clotrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐days clotrimazole 2% vaginal cream once‐daily plus 15‐days concomitant acid pH thymol and zinc‐containing cleansing wash (SaugellaActi3) twice‐daily
Trial: 35759680
Drug: 6‐days clotrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐days clotrimazole treatment alone
Trial: 34493259
Drug: Family-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based intervention using motivational interviewing and principles of cognitive‐behavioral therapy
Trial: 36166727
Drug: Combination nivolumab/ipilimumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination nivolumab/ipilimumab (arm A)
Trial: 36166727
Drug: Combination nivolumab/ipilimumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination nivolumab/ipilimumab (arm D)
Trial: 32656799
Drug: Ongoing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing therapy with lenalidomide
Trial: 34676600
Drug: Thiamidol (applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamidol (applied daily in Dual Serum followed by Day Care SPF30 or Night Care)
Trial: 34676600
Drug: Vehicle (applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (applied daily in corresponding vehicle formulations)
Trial: 33210408
Drug: Curcumagalactomannosides (CGM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumagalactomannosides (CGM) 400 mg once daily
Trial: 33210408
Drug: Glucosamine hydrochloride
RxNorm normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine hydrochloride (GLN) 500 mg and Chondroitin sulphate (CHN) 415 mg, supplied as a single oral dose twice a day
Trial: 34102278
Drug: Dance therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance therapy intervention
Trial: 37639820
Drug: mRNA-1273 COVID-19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 COVID-19 vaccine
Trial: 38191268
Drug: Ebastine 20
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 20 mg
Trial: 35915733
Drug: Conventional western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medicine and massage therapy
Trial: 33882526
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (single agents or in combination)
Trial: 32638504
Drug: MTX (7.5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX (7.5-20 mg/week)
Trial: 34390504
Drug: Low-dose thymoglobulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose thymoglobulin (2.5 mg/kg)
Trial: 35256000
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care and independent exercise with a single therapy session
Trial: 35256000
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care and supervised exercise with three therapy sessions over 12 weeks
Trial: 32586366
Drug: Low-dose UC-MSCs
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose UC-MSCs (3 × 10^6 cells)
Trial: 32586366
Drug: High-dose UC-MSCs
RxNorm normalized name: UC-MSCs
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose UC-MSCs (6 × 10^6 cells)
Trial: 34953526
Drug: Placebo (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5 mL)
Trial: 32527283
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not explicitly defined, but implied as the standard treatment)
Trial: 34700212
Drug: KarXT (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KarXT (a fixed combination of xanomeline and trospium chloride)
Trial: 33412611
Drug: Selatogrel (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selatogrel (16 mg subcutaneous) + Clopidogrel (300 or 600 mg, 30 minutes after selatogrel)
Trial: 33412611
Drug: Selatogrel (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selatogrel (16 mg subcutaneous) + Prasugrel (60 mg, 30 minutes after selatogrel)
Trial: 33412611
Drug: Selatogrel (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selatogrel (16 mg subcutaneous) + Prasugrel (60 mg, 12 hours after selatogrel)
Trial: 33412611
Drug: Selatogrel (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selatogrel (16 mg subcutaneous) + Clopidogrel (300 or 600 mg, 12 hours after selatogrel)
Trial: 33412611
Drug: Selatogrel (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selatogrel (16 mg subcutaneous) + Ticagrelor (180 mg, 30 minutes after selatogrel)
Trial: 33412611
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Clopidogrel (300 or 600 mg, 30 minutes after placebo)
Trial: 33412611
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Prasugrel (60 mg, 30 minutes after placebo)
Trial: 33412611
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Ticagrelor (180 mg, 30 minutes after placebo)
Trial: 32356286
Drug: CORDIS group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORDIS group treatment program (10-week modularized treatment)
Trial: 35358461
Drug: Screening spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening spinal MRI and pre‐emptive treatment for spinal cord compression
Trial: 32306007
Drug: Oral pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pyrotinib (400 mg once daily or 320 mg)
Trial: 33340343
Drug: Cefprozil for
RxNorm normalized name: Cefprozil for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil for suspension (125 mg) under fasted conditions
Trial: 33340343
Drug: Cefprozil for
RxNorm normalized name: Cefprozil for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil for suspension (125 mg) under fed conditions
Trial: 33340343
Drug: Granule formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granule formulation of cefprozil
Trial: 34979962
Drug: Stepped-dose furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stepped-dose furosemide (SF) - continuous infusion of furosemide 100 mg on day 1, with daily incremental doses to 200 mg, 300 mg, and 400 mg.
Trial: 34979962
Drug: Combined diuretics
RxNorm normalized name: atenolol and other diuretics, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined diuretics (CD) - combination of oral chlorthalidone 50 mg, spironolactone 50 mg, and infusion of furosemide 100 mg for 4 consecutive days.
Trial: 34738551
Drug: Nicorandil (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (24 mg/d intravenously for 1 week)
Trial: 35851689
Drug: Metronidazole (MTZ)
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole (MTZ) + Amoxicillin (AMX)
Trial: 32543706
Drug: rhBMP6/ABC (1.0 mg/10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhBMP6/ABC (1.0 mg/10 mL ABC)
Trial: 32543706
Drug: Placebo (10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 mL ABC containing excipients)
Trial: 33176593
Drug: 30 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minutes of NMES daily (Group B)
Trial: 33176593
Drug: 60 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 minutes of NMES daily (Group C)
Trial: 35580859
Drug: Liraglutide in
RxNorm normalized name: Liraglutide Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide in combination with exercise training
Trial: 37204788
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (<120 mm Hg)
Trial: 37204788
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (<140 mm Hg)
Trial: 35006243
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment vs non-Hispanic Black
Trial: 35006243
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment vs non-Hispanic Black
Trial: 35006243
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment vs Hispanic
Trial: 35006243
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment vs Hispanic
Trial: 33828354
Drug: Criminal Justice
RxNorm normalized name: Justicia spicigera leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Criminal Justice (CJ) mandated treatment
Trial: 33828354
Drug: Child Protective
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child Protective Services (CPS) mandated treatment
Trial: 33828354
Drug: Nonmandated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmandated treatment
Trial: 35149566
Drug: Elobixibat (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elobixibat (an ileal bile acid transporter inhibitor)
Trial: 35987909
Drug: Glabellar botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glabellar botulinum toxin (BTX) injections
Trial: 35074904
Drug: High-dose interferon-alfa
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon-alfa (HDI)
Trial: 34120628
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (knee brace and outpatient physical therapy)
Trial: 34120628
Drug: Tailored patella
RxNorm normalized name: Blatella germanica
DrugBank: Blatella germanica (DB10418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored patella stabilizing surgical treatment
Trial: 34016663
Drug: Nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplementation with food rations (750 kcal and 23 g proteins/day) and multivitamins for HHC
Trial: 34016663
Drug: Nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplementation (monthly food rations supplying 1200 kcal and 52 g proteins/day) and multivitamins along with antitubercular treatment for patients
Trial: 35994789
Drug: Nedaplatin 30
RxNorm normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedaplatin 30 mg/m2
Trial: 33082512
Drug: Prednisolone (2–2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (2–2.5 mg/kg)
Trial: 35897006
Drug: rt‐PA +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt‐PA + T group (low-dose rt-PA 0.6 mg/kg + tirofiban for 24 hours)
Trial: 35897006
Drug: rt‐PA group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt‐PA group (standard dose rt-PA 0.9 mg/kg)
Trial: 33482030
Drug: Ultraviolet radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultraviolet radiation (UV) treatment
Trial: 33482030
Drug: Sulphuric acid-based
RxNorm normalized name: Sulfuric Acid
DrugBank: Sulfuric acid (DB11309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphuric acid-based fertilizer (SA) treatment
Trial: 32959431
Drug: Virtual screen‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual screen‐based stress management programme (V‐DESSERTS), individual‐based, twice‐daily sessions
Trial: 33140499
Drug: Group-based motor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based motor and cognitive combined intervention (8-week program, group exercise and cognitive stimulation, twice per week for 45 min)
Trial: 33561623
Drug: Capsaicin (early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin (early administration)
Trial: 38986791
Drug: Oral treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral treprostinil
Trial: 34881930
Drug: Guided self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided self-help cognitive-behavioral therapy (3 months)
Trial: 34819115
Drug: Daily healthy
RxNorm normalized name: Walgreens One Daily Healthy Weight Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily healthy behavior text messaging and weekly self-measured blood pressure monitoring
Trial: 32028393
Drug: Duloxetine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (2 × 40 mg daily) + Pelvic Floor Muscle Training (PFMT) for 12 weeks
Trial: 32028393
Drug: Duloxetine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (2 × 40 mg daily)
Trial: 35836478
Drug: Koji amazake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Koji amazake (118 g/day)
Trial: 32319204
Drug: Low-dose milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose milk protein (pasteurized milk and milk protein powder)
Trial: 32319204
Drug: High-dose milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose milk protein (condensed milk)